Immunohistochemistry-based clinicopathological studies showed that the expression of the CBX1 protein was significantly elevated in human hepatocellular carcinoma (HCC) specimens 12, and CBX2 protein expression was elevated in human prostate cancer tissues 13, predicting a poor outcome in these patients. Here, CBX2 is linked to hepatocellular carcinoma.